FUNDAMENTAL AND CLINICAL STUDIES ON TA-058 IN THE SURGICAL FIELD
A new semisynthetic penicillin TA-058 has been studied. Basic and clinical efficacy in the surgical field were made on. The results were as follows: 1. TA-058 showed relatively excellent antibacterial activities against S. aureus, E. coli and Enterobacter isolated from the surgical lesions. Against...
Saved in:
Published in: | CHEMOTHERAPY Vol. 32; no. Supplement2; pp. 532 - 537 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English Japanese |
Published: |
Japanese Society of Chemotherapy
1984
|
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | A new semisynthetic penicillin TA-058 has been studied. Basic and clinical efficacy in the surgical field were made on. The results were as follows: 1. TA-058 showed relatively excellent antibacterial activities against S. aureus, E. coli and Enterobacter isolated from the surgical lesions. Against P. aeruginosa, the MIC of TA-058 was a little bit higher, so that the administration dosage and method of TA-058 to the infections due to this organism were necessary to be scrutinized in the clinical field. 2. The biliary levels of TA-058 to the patients with drainage were examined. The concentration of TA-058 in bile showed a fluctuation according to the degree of blocked cystic ducts however TA-058 revealed the better transfer into bile. Thus, a good therapeutic response can be expected against biliary tract infections. 3. The concentration of TA-058 in ascites just after operation of gastric tumor was also eninined. The concentration reached to the maximum at 1 hour after intravenous administration of TA-058 2.0g and still, maintained fairly high levels for 4 hours. The results revealed that TA-058 has the good transference into ascites. 4. TA-058 was administered to 8 cases with surgical infections, and the clinical response was excellent in 1 case, good in 5 cases, fair in 1 case and poor in 1 case. No noteworthy side effect attributalble to the drug was observed. |
---|---|
ISSN: | 0009-3165 1884-5894 |
DOI: | 10.11250/chemotherapy1953.32.Supplement2_532 |